Intra-Cellular Therapies, Inc. (ITCI)

Intra-Cellular Therapies Revenue

Intra-Cellular Therapies had revenue of $513.93M in the twelve months ending March 31, 2024, with 65.45% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $144.87M with 52.00% year-over-year growth. In the year 2023, Intra-Cellular Therapies had annual revenue of $464.37M with 85.51% growth.

• Revenue (ttm): $513.93M
• Revenue Growth: +65.45%
• P/S Ratio: 15.38
• Revenue / Employee: $842,508
• Employees: 610
• Market Cap: 7.90B USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	464.37M	214.06M	85.51%
Dec 31, 2022	250.31M	166.51M	198.69%
Dec 31, 2021	83.80M	60.99M	267.35%
Dec 31, 2020	22.81M	22.75M	37,537.14%
Dec 31, 2019	60.61K	-	-
Dec 31, 2018	0	-	-
Dec 31, 2017	245.84K	-84.87K	-25.66%
Dec 31, 2016	330.70K	239.34K	261.96%
Dec 31, 2015	91.36K	-485.94K	-84.17%
Dec 31, 2014	577.30K	-2.16M	-78.91%
Dec 31, 2013	2.74M	-380.99K	-12.22%
Dec 31, 2012	3.12M	-20.24M	-86.65%
Dec 31, 2011	23.36M	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.